Last reviewed · How we verify

Placebo for ABT-493/ABT-530

AbbVie · Phase 3 active Small molecule

Placebo for ABT-493/ABT-530 is a Small molecule drug developed by AbbVie. It is currently in Phase 3 development.

This is a placebo control with no active pharmacological mechanism.

At a glance

Generic namePlacebo for ABT-493/ABT-530
SponsorAbbVie
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebo is an inert substance used as a control arm in clinical trials to establish the efficacy of the active investigational drugs ABT-493 and ABT-530. It contains no active pharmaceutical ingredient and serves to blind trial participants and assess the baseline disease progression or response attributable to non-pharmacological factors.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo for ABT-493/ABT-530

What is Placebo for ABT-493/ABT-530?

Placebo for ABT-493/ABT-530 is a Small molecule drug developed by AbbVie.

How does Placebo for ABT-493/ABT-530 work?

This is a placebo control with no active pharmacological mechanism.

Who makes Placebo for ABT-493/ABT-530?

Placebo for ABT-493/ABT-530 is developed by AbbVie (see full AbbVie pipeline at /company/abbvie).

What development phase is Placebo for ABT-493/ABT-530 in?

Placebo for ABT-493/ABT-530 is in Phase 3.

Related